Keenova Therapeutics plc

Keenova Therapeutics is a purpose-driven pharmaceutical company focused on developing, manufacturing, and commercializing branded therapeutics for patients with rare or unaddressed conditions. Headquartered in Dublin, Ireland, with a significant U.S.-focused commercial and manufacturing presence, the company operates under the tagline "Keen to Solve, Keen to Serve," reflecting its commitment to improving patient lives.

The company's portfolio spans diverse therapeutic areas, including immunology, urology, hepatology, ophthalmology, orthopedics, critical care, rheumatology, nephrology, pulmonology, neurology, and pediatric endocrinology. Key products include TERLIVAZ® (terlipressin) for hepatorenal syndrome-acute kidney injury, XIAFLEX® (collagenase clostridium histolyticum) for Dupuytren's contracture and Peyronie's disease, and Acthar® Gel (repository corticotropin injection) for inflammatory and autoimmune conditions.

Keenova Therapeutics was established in November 2025, emerging from the merger of Mallinckrodt and Endo Pharmaceuticals' branded businesses, following the spin-off of their generics and sterile injectables unit, Par Health. Led by CEO Siggi Olafsson, the company reported a pro-forma combined revenue of $1.7 billion in 2024 and employs over 1,600 individuals. Keenova intends to pursue a listing of its ordinary shares on the New York Stock Exchange in 2026.